Biotech RadarJobs updated

COMPANY

Oui Therapeutics, Inc.

HQ: New Haven, CT source · ouitherapeutics.com ↗ · New England

Clinical Phase 3

Oui Therapeutics, Inc.'s website says: "We have been involved in bringing new classes of FDA regulated products to market (including new mechanisms of action for diseases including schizophrenia)." From company website Source · Oct 13, 2026

Keywords: Post Traumatic Stress Disorder Suicidal Ideation PTSD Attempted Suicide Obesity Binge Eating OTX-601 Digital Therapeutic - Version 1 OTX-601 Digital Therapeutic - Version 2 OTX-601 Digital Therapeutic OTX-003 Comparator app OTX-207 OTX-202 OTX-000 OTX-401 Software Application

Location: New Haven, CT · source · Oct 15, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)12NIH grants

Funding and NIH signals

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

  1. Grant Government grant — SBIR: $966,804 (annual award, as published), announced Jul 28, 2026. Agency: NIH/NIMH. Source: government award database. source ↗
  2. Trial start Phase 2: Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms source ↗
  3. Trial start Not phased (device or behavioral study): Pilot Trial of Mobile Technology for Adolescent Suicidality source ↗
  4. Grant Government grant — STTR: $596,110 (annual award, as published), announced Jul 31, 2025. Agency: NIH/NIMH. Source: government award database. source ↗
  5. Trial start Phase 1: Feasibility of a Digital Therapeutic for Adults With Posttraumatic Stress Disorder (PTSD) source ↗
  6. Grant Government grant — SBIR: $417,356 (annual award, as published), announced Jun 10, 2025. Agency: NIH/NIMH. Source: government award database. source ↗
  7. Trial start Not phased (device or behavioral study): Feasibility of a Digital Therapeutic for Adults With Binge Eating and Obesity source ↗
  8. Trial start Phase 2/Phase 3: A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic source ↗
  9. Trial start Not phased (device or behavioral study): Feasibility Study of a Software Application for Patients Hospitalized After Suicidal Ideation or Suicide Attempts source ↗

Funding

Last 2 years.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT06868446Feasibility of a Digital Therapeutic for Adults With Posttraumatic Stress Disorder (PTSD)Phase 1CompletedJun 30, 2025Nov 18, 2025 (actual)
NCT07316088Determining the Potential for Efficacy of OTX-601 in Reducing PTSD SymptomsPhase 2Active, not recruitingDec 9, 2025Jul 31, 2026 (estimated)
NCT06454136Pilot Trial of Mobile Technology for Adolescent SuicidalityNot phased (device or behavioral study)Enrolling by invitationOct 23, 20252026-06 (estimated)
NCT05144685A Study to Evaluate the Safety and Effectiveness of a Digital TherapeuticPhase 2/Phase 3TerminatedApr 7, 2022Jun 14, 2024 (actual)
NCT06454123Feasibility of a Digital Therapeutic for Adults With Binge Eating and ObesityNot phased (device or behavioral study)Unknown status (ClinicalTrials.gov)2024-092025-03 (estimated)
NCT04295382Feasibility Study of a Software Application for Patients Hospitalized After Suicidal Ideation or Suicide AttemptsNot phased (device or behavioral study)CompletedMay 12, 2020Jul 1, 2021 (actual)

NIH awards 12

Annual award amounts. Total $6.7M.

Feedback